Indicated for: osteoporosis
Route of administration: oral
Substance: risedronic acid (bisphosphonate)
ATC: M05BA07 (Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates)
Risedronic acid is a bisphosphonate used for the prevention and treatment of osteoporosis, particularly in postmenopausal women. It is also used to treat Paget's disease of the bone.
It works by inhibiting the activity of osteoclasts, the cells responsible for bone resorption, leading to increased bone density and reduced risk of fractures. It is taken orally, usually once a week or once a month, depending on the indication.
Common side effects include gastrointestinal disturbances such as nausea, abdominal pain, and heartburn. In rare cases, it may cause osteonecrosis of the jaw or atypical femur fractures.
Patients taking risedronic acid should follow administration instructions, such as taking the medication on an empty stomach and avoiding lying down for 30 minutes after taking it, to reduce the risk of esophageal irritation.